Drug intelligence / Profile preview

UX-UD

Development stage: Preclinical
Lead developer: UniXell Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intracerebral

Overview

UX-UD is an early-stage cell therapy candidate under development by Shanghai UniXell Biotechnology. As part of a pipeline focused on human induced pluripotent stem cell (hiPSC)-derived products, UX-UD is currently in the research and development (R&D) phase for an undisclosed indication. The therapy leverages the company's core technology platforms, which include innovative reprogramming, high-precision gene editing, and SISBAR pedigree tracing to produce specialized cell types for regenerative medicine. Due to its early stage of development, specific details regarding the target cell type and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on UX-UD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UX-UD.

Explore the full profile